Redhill Biopharma Ltd (RDHL) - Total Liabilities

Latest as of March 2026: $21.08 Million USD

Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has total liabilities worth $21.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Redhill Biopharma Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

Redhill Biopharma Ltd - Total Liabilities Trend (2010–2025)

This chart illustrates how Redhill Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Redhill Biopharma Ltd (RDHL) total assets.

Redhill Biopharma Ltd Competitors by Total Liabilities

The table below lists competitors of Redhill Biopharma Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Mare Nostrum PA:ALMAR	France	€80.01 Million
Nrgene Technologies Ltd TA:NRGN	Israel	ILA5.12 Million
MANTLE MINERALS F:MXB0	Germany	€871.45K
Sparta Capital Ltd V:SAY	Canada	CA$3.68 Million
Techgen Metals Ltd AU:TG1	Australia	AU$102.12K
Marston’s PLC LSE:MARS	UK	GBX1.53 Billion
Social Housing REIT plc LSE:SOHO	UK	GBX266.00 Million
South HARZ Potash Ltd AU:SHP	Australia	AU$1.16 Million

Liability Composition Analysis (2010–2025)

This chart breaks down Redhill Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Redhill Biopharma Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.34	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	4.94	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.83	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Redhill Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Redhill Biopharma Ltd (2010–2025)

The table below shows the annual total liabilities of Redhill Biopharma Ltd from 2010 to 2025.

Year	Total Liabilities	Change
2025-12-31	$21.08 Million	-7.26%
2024-12-31	$22.73 Million	+8.33%
2023-12-31	$20.98 Million	-89.88%
2022-12-31	$207.27 Million	+20.29%
2021-12-31	$172.31 Million	+3.57%
2020-12-31	$166.38 Million	+1080.23%
2019-12-31	$14.10 Million	+25.59%
2018-12-31	$11.22 Million	-8.58%
2017-12-31	$12.28 Million	+6.66%
2016-12-31	$11.51 Million	+70.51%
2015-12-31	$6.75 Million	+75.58%
2014-12-31	$3.85 Million	+59.21%
2013-12-31	$2.42 Million	+124.03%
2012-12-31	$1.08 Million	-22.94%
2011-12-31	$1.40 Million	-88.44%
2010-12-31	$12.10 Million	--

About Redhill Biopharma Ltd

NASDAQ:RDHL USA Drug Manufacturers - Specialty & Generic

Market Cap

$3.60 Million

Market Cap Rank

#29271 Global

#5979 in USA

Share Price

$0.59

Change (1 day)

+7.78%

52-Week Range

$0.55 - $2.52

All Time High

$16290.00